Molina Q3 2026 Call Serves as Checkpoint for Marketplace and Florida Thesis

What happened

Molina Healthcare held its Q3 2026 earnings call on October 22, 2026, as anticipated by the DeepValue report. The report had identified Q3 and Q4 2026 as the period to test whether Marketplace MCR improved from 88.9% and whether the Florida Medicaid launch stayed on track for Q4 2026. Management's commentary during the call would address these points, but the transcript excerpt provided only the participant list and operator introduction. Therefore, no new financial data is available from this article to alter the existing thesis. The call remains a critical data point for investors following the WAIT rating.

Implication

Investors should await the full earnings release and call details to confirm whether Marketplace MCR improved from 88.9% and whether Florida start-up losses remain within the -$1.50 EPS assumption. If the call shows improvement, the thesis could shift toward a more constructive stance, but without specifics, the WAIT rating remains appropriate. The stock's pre-call price near $195 leaves limited upside to the report's trimmed valuation of $235. A pullback toward $175 would offer a better entry if fundamentals are stabilizing. Conversely, any indication that Marketplace economics remain weak or Florida is delayed would reinforce downside risk toward $160.

Thesis delta

The Q3 2026 earnings call did not provide new information in the transcript excerpt, so the thesis delta is neutral. The key triggers for a rating change remain unchanged: Marketplace MCR below 87% or above 88.9%, and Florida launch execution. Until full call details emerge, the WAIT rating and conviction level of 4.0 remain appropriate.